RESUMO
BACKGROUND: The prevalence of gastroesophageal reflux disease (GERD) has been increasing worldwide, with proton pump inhibitor (PPI) administration the current mainstay therapy for affected individuals. However, PPI efficacy is insufficient especially for non-erosive reflux disease. Although it has been reported that prokinetic drugs improve GERD, their effects on esophageal function remain to be clearly investigated. In the present study, we evaluated the direct effects of acotiamide, a novel prokinetic agent for the treatment of functional dyspepsia, on esophageal motor function and gastroesophageal reflux. METHODS: Ten adult healthy volunteers (average age 24 years, range 20-36 years; 7 males, 3 females) were enrolled. Esophageal body peristaltic contractions and lower esophageal sphincter (LES) pressure with and without acotiamide administration were recorded using high resolution manometry using a cross-over protocol. Total and acidic reflux levels for 24 h and during the postprandial period were also recorded using a multichannel intraluminal impedance and pH monitoring system. Data were analyzed blind by one observer. RESULTS: Acotiamide at a standard dose of 300 mg/day did not significantly stimulate esophageal motor function. Although the frequency of swallows with weak contraction tended to decrease with acotiamide administration, the difference as compared to no administration was not statistically significant. In addition, the drug neither decreased total or postprandial gastroesophageal acid/non-acid reflux events nor accelerated esophageal clearance time. CONCLUSIONS: Acotiamide, a novel gastrointestinal motility modulator, at a standard dose did not significantly affect esophageal motor functions or gastroesophageal reflux in healthy adults. Additional investigations with GERD patients are necessary to elucidate its clinical significance. TRIAL REGISTRATION: This study was registered on 1st August 2013 with the University Hospital Medical Information Network (UMIN) clinical trials registry, as number: UMIN000011260.
Assuntos
Benzamidas/uso terapêutico , Esfíncter Esofágico Inferior/efeitos dos fármacos , Refluxo Gastroesofágico/tratamento farmacológico , Fármacos Gastrointestinais/uso terapêutico , Peristaltismo/efeitos dos fármacos , Tiazóis/uso terapêutico , Adulto , Benzamidas/farmacologia , Estudos Cross-Over , Impedância Elétrica , Esfíncter Esofágico Inferior/fisiologia , Monitoramento do pH Esofágico , Feminino , Fármacos Gastrointestinais/farmacologia , Voluntários Saudáveis , Humanos , Masculino , Manometria , Período Pós-Prandial , Tiazóis/farmacologia , Adulto JovemRESUMO
Cytoglobin (Cygb) is a recently discovered vertebrate globin with molecular characteristics that are similar to myoglobin. To study the biological function of Cygb in vivo, we generated Cygb knockout mice and investigated their susceptibility to N,N-diethylnitrosamine (DEN)-induced tumorigenesis. Four-week-old male mice were administered DEN in drinking water at a dose of 25 ppm for 25 weeks or 0.05 ppm for 36 weeks. Cygb deficiency promoted the DEN-induced development of liver and lung tumors. All Cygb(+/-) and Cygb(-/-) mice treated with 25-ppm DEN exhibited liver tumors, compared with 44.4% of their wild-type counterparts. Lung tumors were present only in Cygb-deficient mice. More than 40% of Cygb(-/-) mice developed liver and lung tumors at the nontoxic dose of DEN (0.05 ppm), which did not induce tumors in wild-type mice. Cygb loss was associated with increased cancer cell proliferation, elevated extracellular signal-regulated kinase and Akt activation, overexpression of IL-1ß, IL-6, Tnfα, and Tgfß3 mRNAs, and hepatic collagen accumulation. Cygb-deficient mice also exhibited increased nitrotyrosine formation and dysregulated expression of cancer-related genes (cyclin D2, p53, Pak1, Src, Cdkn2a, and Cebpa). These results suggest that Cygb deficiency induces susceptibility to cancer development in the liver and lungs of mice exposed to DEN. Thus, globins such as Cygb will shed new light on the biological features of organ carcinogenesis.
Assuntos
Dietilnitrosamina/farmacologia , Globinas/genética , Neoplasias Hepáticas/metabolismo , Neoplasias Pulmonares/metabolismo , Alquilantes/farmacologia , Animais , Proliferação de Células , Citoglobina , Relação Dose-Resposta a Droga , Éxons , Feminino , Regulação Neoplásica da Expressão Gênica , Vetores Genéticos , Globinas/metabolismo , Neoplasias Hepáticas/induzido quimicamente , Neoplasias Pulmonares/induzido quimicamente , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Camundongos Transgênicos , Modelos GenéticosRESUMO
BACKGROUND: Several noninvasive tests have been proposed to predict cirrhosis in patients with chronic hepatitis C, but not in patients with non-alcoholic steatohepatitis (NASH). We assessed whether noninvasive laboratory tests designed to predict the risk of cirrhosis in patients with chronic hepatitis C virus (HCV) infection could be used in patients with NASH. METHODS: The subjects were 50 patients with biopsy-proved NASH and 100 age- and sex-matched patients with HCV. Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio (AAR), age-platelet (AP) index, AST-to-platelet ratio index (APRI), cirrhosis discriminant score (CDS), and the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) model were calculated. RESULTS: The areas under the receiver-operating characteristic curves of the AAR, AP index, APRI, CDS, and HALT-C model for predicting cirrhosis were respectively 0.813, 0.877, 0.786, 0.949, and 0.908 in patients with NASH and 0.555, 0.652, 0.761, 0.782, and 0.782 in patients with HCV. A CDS cutoff value of less than 5 misclassified none of the 9 patients with NASH who had cirrhosis, while a value of more than 8 misclassified none of the 41 patients with NASH without cirrhosis. With the HALT-C model, a cutoff value of less than 0.6 classified non-cirrhotic NASH, while a cutoff value of 0.97 or higher classified cirrhotic NASH. The use of CDS and HALT-C model could avoid liver biopsy for predicting cirrhosis in 60 and 48% of the patients with NASH, respectively. CONCLUSIONS: Noninvasive laboratory tests designed to predict cirrhosis in patients with HCV are also useful in patients with NASH.
Assuntos
Fígado Gorduroso/complicações , Cirrose Hepática/etiologia , Testes de Função Hepática , Adulto , Idoso , Alanina Transaminase/sangue , Aspartato Aminotransferases/sangue , Feminino , Hepatite C Crônica/complicações , Humanos , Cirrose Hepática/virologia , Testes de Função Hepática/métodos , Testes de Função Hepática/normas , Masculino , Pessoa de Meia-Idade , Contagem de Plaquetas , Valor Preditivo dos Testes , Curva ROCRESUMO
In biointegrated electronics, the facile control of mechanical properties such as softness and stretchability in electronic devices is necessary to minimize the perturbation of motions inherent in biological systems1-5. For in vitro studies, multielectrode-embedded dishes6-8 and other rigid devices9-12 have been widely used. Soft or flexible electronics on plastic or elastomeric substrates13-15 offer promising new advantages such as decreasing physical stress16-18 and/or applying mechanical stimuli19,20. Recently, owing to the introduction of macroporous plastic substrates with nanofibre scaffolds21,22, three-dimensional electrophysiological mapping of cardiomyocytes has been demonstrated. However, quantitatively monitoring cells that exhibit significant dynamical motions via electric probes over a long period without affecting their natural motion remains a challenge. Here, we present ultrasoft electronics with nanomeshes that monitor the field potential of human induced pluripotent stem cell-derived cardiomyocytes on a hydrogel, while enabling them to move dynamically without interference. Owing to the extraordinary softness of the nanomeshes, nanomesh-attached cardiomyocytes exhibit contraction and relaxation motions comparable to that of cardiomyocytes without attached nanomeshes. Our multilayered nanomesh devices maintain reliable operations in a liquid environment, enabling the recording of field potentials of the cardiomyocytes over a period of 96 h without significant degradation of the nanomesh devices or damage of the cardiomyocytes.
Assuntos
Eletrônica/instrumentação , Miócitos Cardíacos/citologia , Impedância Elétrica , Humanos , Células-Tronco Pluripotentes Induzidas/citologia , Nanopartículas/química , Imagem ÓpticaRESUMO
Thin-film electronic devices can be integrated with skin for health monitoring and/or for interfacing with machines. Minimal invasiveness is highly desirable when applying wearable electronics directly onto human skin. However, manufacturing such on-skin electronics on planar substrates results in limited gas permeability. Therefore, it is necessary to systematically investigate their long-term physiological and psychological effects. As a demonstration of substrate-free electronics, here we show the successful fabrication of inflammation-free, highly gas-permeable, ultrathin, lightweight and stretchable sensors that can be directly laminated onto human skin for long periods of time, realized with a conductive nanomesh structure. A one-week skin patch test revealed that the risk of inflammation caused by on-skin sensors can be significantly suppressed by using the nanomesh sensors. Furthermore, a wireless system that can detect touch, temperature and pressure is successfully demonstrated using a nanomesh with excellent mechanical durability. In addition, electromyogram recordings were successfully taken with minimal discomfort to the user.
Assuntos
Técnicas Biossensoriais/instrumentação , Eletromiografia/instrumentação , Eletrônica Médica/instrumentação , Nanoestruturas/química , Pele , Adulto , Materiais Biocompatíveis/efeitos adversos , Materiais Biocompatíveis/química , Bioengenharia/instrumentação , Condutividade Elétrica , Gases/química , Humanos , Inflamação/etiologia , Pessoa de Meia-Idade , Nanoestruturas/efeitos adversos , Nanoestruturas/ultraestrutura , Nanotecnologia/instrumentação , Permeabilidade , Pele/metabolismo , Adulto JovemRESUMO
AIM: Transient elastography is known as a rapid, objective, and highly reliable technique for staging hepatic fibrosis caused by hepatitis C virus infection; however, the relationship between degree of fibrosis and the collagen deposition or the accumulation of myofibroblasts in non-alcoholic fatty liver disease (NAFLD) remains to be further elucidated. METHODS: The subjects were 36 patients with NAFLD who received liver biopsy and liver stiffness measurement using transient elastography. Their clinical data and laboratory values were collected. Morphometric analyses of liver fibrosis indicated by collagen deposition and the relative numbers of myofibroblasts were performed. RESULTS: Liver stiffness measured by transient elastography correlated with histopathological fibrosis staging of NAFLD determined by Brunt's scoring system (P = 0.000149). The fibrosis staging correlated with the ratios of the Sirius red-positive area (P = 0.000032) and α-smooth muscle actin-positive area (P = 0.000898). Finally, liver stiffness significantly correlated with the ratios of the Sirius red-positive area (r = 0.390, P = 0.0184) and α-smooth muscle actin-positive area (r = 0.333, P = 0.0471). CONCLUSIONS: Liver stiffness measurement by transient elastography is valuable for evaluating fibrotic progression in NAFLD.
RESUMO
AIM: The usefulness of transient elastography remains to be validated in chronic hepatitis B, particularly as a tool for monitoring the degree of liver fibrosis during treatment. METHODS: The subjects were 50 patients with chronic hepatitis B virus infection. Liver biopsy was performed in 38 patients, and in 12 patients with platelet counts of 50 × 10(9)/L or less, cirrhosis was clinically diagnosed on the basis of specific signs of portal hypertension. Liver stiffness was measured by transient elastography at baseline and after 12 months of treatment in 20 nucleos(t)ide-naïve patients who started entecavir within 3 months after study entry. RESULTS: Twenty (40%) patients were classified as F1, 10 (20%) as F2, 5 (10%) as F3, and 15 (30%) as F4 (cirrhosis). Median liver stiffness (interquartile range) was 7.0 kPa (5.6-9.4), 9.8 kPa (5.6-14.7), 9.8 kPa (7.6-12.9), and 17.3 kPa (8.2-27.6) in fibrosis stages F1 to F4, respectively. Liver stiffness significantly correlated with fibrosis stage (r = 0.46; P = 0.0014). Of the patients who started entecavir, median liver stiffness significantly decreased from 11.2 kPa (7.0-15.2) to 7.8 kPa (5.1-11.9; P = 0.0090) during 12 months of treatment. Median levels of amino-terminal peptide of type III procollagen and type IV collagen 7S domain in serum significantly decreased from 0.9 (0.6-1.3) to 0.6 (0.5-0.7) U/mL (P = 0.0010) and from 5.0 (4.4-6.7) to 3.9 (3.2-4.4) ng/mL (P = 0.015), respectively. CONCLUSION: Liver stiffness measurement can be useful for monitoring regression of liver fibrosis during entecavir treatment in patients with chronic hepatitis B virus infection.